Summary

IPO quiet period for TOCA expires on 5.8; on 5.9 underwriters Evercore, Leerink, and Stifel will likely release positive reports.

We believe the event will lead to a short-term price increase, given our firm’s research, and suggest investors purchase TOCA shares ahead of the event to gain.

TOCA has performed well in its early market debut and IPO proceeds will likely expedite clinical trials.

Tocagen Incorporated (Pending:TOCA) – Buy Recommendation – $15.25.

The 25-day quiet period on underwriter analyses that began with the April 13, 2017, IPO of Tocagen Inc. will come to an end on May 8, allowing the firm’s many underwriters to publish detailed positive reports and recommendations on Tocagen on May 9.

Tocagen’s share price will likely see a temporary increase as a result of the release of (likely very positive) underwriter reports. We suggest investors consider buying TOCA prior to the event.

(See the end of this article for a more detailed discussion of the timing considerations for an investment.)

Business Overview: Clinical-stage Company Developing Gene Therapies Targeting Cancer

(Source: Company Website)

Tocagen is a clinical-stage company developing cancer-selective gene therapies with product candidates designed to activate a patient’s immune system. The company’s proprietary platform works with retroviral replicating vectors (RRVs) that deliver therapeutic genes into the DNA of cancer cells. This system seeks to work without the autoimmune toxicities that are common with other immunotherapies.

Tocagen is developing Toca 511 & Toca FC that is in Phase II/III clinical trial for patients with recurrent high grade glioma (HGG); and Phase Ib clinical trial for the intravenous treatment of renal, melanoma, lung, breast, pancreatic, and metastatic colo-rectal cancers, as well as in preclinical stage for newly diagnosed HGG. Tocagen is also developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets, such as the checkpoint protein PD-L1.